UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006113
Receipt number R000005050
Scientific Title A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.
Date of disclosure of the study information 2011/08/04
Last modified on 2013/08/03 16:19:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

Acronym

A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

Scientific Title

A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

Scientific Title:Acronym

A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

Region

Japan


Condition

Condition

Previously untreated lung adenocarcinoma

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety of pemetrexed for elderly patients with previously untreated lung adenocarcinoma, and to explore mechanism of resistance for pemetrexed in pathological aspect..

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

one year survival rate

Key secondary outcomes

overall survival, progression-free survival, objective response rate, adverse effects.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pemetrexed (500mg/m2) day 1,q3~5w until disease progression

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Histologically or cytologically proven lung adenocarcinoma
2. No indication for platinum doublet therapy
3. With measurable lesion based on RECIST
4. Previously untreated
5. ECOG PS 0-2
6. 70 years or older
7. Adequate organ function
8. Eligible in case of controlled pleural effusion
9)Eligible in case of controlled brain metastases
10)Written informed consent

Key exclusion criteria

1. Symptomatic brain metastasis
2. Massive pleural effusion
3. Hystory of active double cancer
4. History of uncontrollable diabetes mellitus, active angina pectoris, recent myocardial infaction, and severe complications
5. History of active infection

Target sample size

32


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuyoshi Kuwano

Organization

Jikei University Hospital

Division name

Division of Respirology, department of internal medicine

Zip code


Address

3-25-8, Nishi-Shimbashi, Minato-ku,Tokyo, 105-8461

TEL

03-3433-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yoshitaka Seki

Organization

Jikei University Daisan-Hospital

Division name

Division of Respirology, department of internal medicine

Zip code


Address

4-11-1, Izumi-honcho, Komae-shi, Tokyo, 201-8601 Japan

TEL

03-3480-1151

Homepage URL


Email

ms97-seki@jikei.ac.jp


Sponsor or person

Institute

Division of Respirology, department of internal medicine, Jikei University Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京慈恵会医科大学付属病院


Other administrative information

Date of disclosure of the study information

2011 Year 08 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 09 Month 15 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 01 Day

Last follow-up date

2013 Year 09 Month 01 Day

Date of closure to data entry

2013 Year 12 Month 01 Day

Date trial data considered complete

2013 Year 12 Month 01 Day

Date analysis concluded

2014 Year 01 Month 01 Day


Other

Other related information



Management information

Registered date

2011 Year 08 Month 03 Day

Last modified on

2013 Year 08 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005050


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name